StockVS

Waldencast plc (WALDW) 股票分析

Waldencast plc

$0.04

+$0.00 (+9.83%)

最后更新: 2026年5月26日

价格走势

分析

公司概述

Waldencast plc operates within the beauty and wellness sector, serving a global customer base across the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand. The company's business model focuses on providing skin care products designed to minimize signs of skin aging and address dark spots, functioning through two distinct segments: Obagi Medical and Milk Makeup. Although specific sector and industry classifications are not publicly disclosed in the provided data, the entity manages a substantial operational scale with a total workforce of 367 employees. The company's financial positioning is characterized by a market capitalization that is not currently quantified in the available facts, yet it generates an annual revenue of $272.07 million, indicating a significant revenue base for its operational scope. These revenue figures suggest that the company holds a notable position in the international beauty market, supported by a dedicated team of nearly 400 professionals who facilitate product distribution and brand management across diverse geographical regions.

财务健康

The company reported a trailing twelve-month revenue of $272.07 million, yet this top-line figure is contrasted by a net income of -$229,748,992 and an EBITDA of -$5,782,000, revealing a substantial gap between gross sales and bottom-line profitability. This disparity between revenue and net income highlights a cost structure where operating expenses and other deductions significantly erode pre-tax earnings, resulting in a negative profit environment. Despite the negative earnings, the company maintains a free cash flow of $115.17 million, which provides a critical buffer for financial flexibility and operational continuity despite the reported net losses. In terms of cash positioning, Waldencast holds $30.38 million in cash against a total debt load of $149.01 million, resulting in a debt-to-equity ratio of 29.80. This leverage profile indicates a balance sheet that is heavily reliant on debt financing relative to shareholder equity, which introduces potential financial risk if cash flows were to deteriorate further. Liquidity is supported by a current ratio of 1.70, suggesting the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin. Return on equity stands at -40.3% and return on assets is -4.7%, metrics that collectively reveal that management has not yet achieved positive capital efficiency or effective utilization of shareholder capital to generate returns.

估值评估

Valuation multiples for Waldencast are unavailable in the current dataset, as the P/E Ratio (TTM), Forward P/E, and Price to Sales metrics are listed as N/A. The absence of a trailing P/E and forward P/E implies that traditional earnings-based valuation models cannot be applied due to the company's negative net income and lack of reported earnings data. Similarly, the EV/EBITDA metric is not provided, preventing a comparison of enterprise value relative to operating earnings for valuation context. However, the price-to-book ratio is recorded at 0.01, which indicates that the market capitalization is trading at a fraction of the company's net asset value, suggesting a deep discount relative to book value. Price sensitivity is evident in the stock's trading range, with a 52-week high of $0.12 and a 52-week low of $0.02. Without a specific current price provided in the facts, the trading position relative to this range remains undefined, but the spread between the high and low demonstrates significant intrayear volatility. The stock exhibits a beta of -0.07, a negative value that is anomalous for standard equity instruments and suggests price movements that do not correlate positively with the broader market index.

Growth & Income

Revenue growth year-over-year is recorded at -1.7%, while earnings growth is listed as N/A due to the negative earnings history. The negative revenue growth rate indicates a slight contraction in top-line sales, whereas the lack of earnings growth data prevents a direct comparison of profitability expansion relative to revenue changes. Waldencast does not pay a dividend, evidenced by a dividend yield and payout ratio that are both N/A, meaning the company does not distribute cash to shareholders. Consequently, the company retains all its earnings, or in this case, accumulates losses, to fund operations and potentially reduce its substantial debt burden rather than rewarding shareholders with income. The overall growth and income profile is characterized by revenue contraction, negative profitability, and a lack of dividend distribution, reflecting a capital-intensive or restructuring phase in the company's lifecycle.

本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。

关于Waldencast plc

Waldencast plc operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand. The company operates through two segments, Obagi Medical and Milk Makeup. It offers skin care products to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and protect and enhance skin tone and texture; cosmetics; and other beauty products. In addition, the company provides foundation, concealer, primer, blush, setting spray, and bronzer categories, as well as sells liner, eyeshadow, and lip color products. It serves distributors, retailers, physicians, and directly to consumers through its e-commerce platforms, and third-party logistics and delivery providers. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

公司简介以英文显示。

访问官网 →

关键指标

市值
N/A
市盈率
N/A
52周最高
$0.11
52周最低
$0.02
平均成交量
45.35K
Beta系数
-0.10

数据由Yahoo Finance通过yfinance提供。每日更新。

公司信息

交易所
NASDAQ
国家
United Kingdom
员工数
367